161 related articles for article (PubMed ID: 27720311)
1. Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients.
Katayama N; Yorozu A; Maruo S; Kojima S; Ohashi T; Tanaka N; Kikuchi T; Higashide S; Saito S; Dokiya T; Fukushima M; Yamanaka H
Brachytherapy; 2016; 15(6):736-745. PubMed ID: 27720311
[TBL] [Abstract][Full Text] [Related]
2. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
4. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
5. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
[TBL] [Abstract][Full Text] [Related]
6. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study.
Nakano M; Yorozu A; Saito S; Sugawara A; Maruo S; Kojima S; Kikuchi T; Fukushima M; Dokiya T; Yamanaka H
Radiat Oncol; 2015 Nov; 10():228. PubMed ID: 26577301
[TBL] [Abstract][Full Text] [Related]
7. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy.
Tanaka N; Asakawa I; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2013 Jan; 8():25. PubMed ID: 23363647
[TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
10. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
Ellis RJ; Zhou H; Kaminsky DA; Fu P; Kim EY; Sodee DB; Colussi V; Spirnak JP; Whalen CC; Resnick MI
Brachytherapy; 2007; 6(2):149-56. PubMed ID: 17434109
[TBL] [Abstract][Full Text] [Related]
11. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS).
Koga H; Naito S; Ishiyama H; Yorozu A; Saito S; Kojima S; Higashide S; Kikuchi T; Nakamura K; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(6):806-813. PubMed ID: 31378511
[TBL] [Abstract][Full Text] [Related]
13. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
14. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
16. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
17. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.
Price JG; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):842-7. PubMed ID: 23845840
[TBL] [Abstract][Full Text] [Related]
19. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
20. Novel parameter predicting grade 2 rectal bleeding after iodine-125 prostate brachytherapy combined with external beam radiation therapy.
Shiraishi Y; Hanada T; Ohashi T; Yorozu A; Toya K; Saito S; Shigematsu N
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):182-7. PubMed ID: 23747214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
